Naproxen
- Generic Name
- Naproxen
- Brand Names
- Aleve, Aleve PM, Aleve-D, Anaprox, Naprelan, Naprosyn, Sallus, Sudafed Sinus & Pain, Treximet, Vimovo
- Drug Type
- Small Molecule
- Chemical Formula
- C14H14O3
- CAS Number
- 22204-53-1
- Unique Ingredient Identifier
- 57Y76R9ATQ
- Background
Naproxen is classified as a nonsteroidal anti-inflammatory dug (NSAID) and was initially approved for prescription use in 1976 and then for over-the-counter (OTC) use in 1994. It can effectively manage acute pain as well as pain related to rheumatic diseases, and has a well studied adverse effect profile. Given its overall tolerability and effectiveness, nap...
- Indication
Naproxen is indicated for the management of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, polyarticular juvenile idiopathic arthritis, tendinitis, bursitis, acute gout, primary dysmenorrhea, and for the relief of mild to moderate pain. Further, it is first-line therapy for osteoarthritis, acute gouty arthritis, dysmenorrhea, and musculoskelet...
- Associated Conditions
- Acute Gouty Arthritis, Acute Migraine, Ankylosing Spondylitis (AS), Back pain, Bursitis, Extra-Articular Rheumatism, Fever, Flu caused by Influenza, Headache, Juvenile Idiopathic Arthritis (JIA), Menstrual Distress (Dysmenorrhea), Migraine, Muscle Spasms, Nasal Congestion, Osteoarthritis (OA), Pain, Post Traumatic Pain, Postoperative pain, Primary Dysmenorrhoea, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Seasonal Allergic Rhinitis, Sinusitis, Tendinitis, Toothache, Articular inflammation
- Associated Therapies
- -
A Study To Investigate Whether PF-04457845 Is Effective In Treating Pain, Is Safe And Tolerable In Patients With Osteoarthritis Of The Knee
- First Posted Date
- 2009-09-22
- Last Posted Date
- 2017-09-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 76
- Registration Number
- NCT00981357
- Locations
- 🇺🇸
Arthritis & Rheumatic Care Center, Miami, Florida, United States
🇺🇸CEDRA Clinical Research, LLC, San Antonio, Texas, United States
🇸🇪Centrum for klinisk provning, Goteborg, Sweden
Oral Bioequivalence Study of PL 3100 and Naproxen in Healthy Adults
- First Posted Date
- 2009-08-27
- Last Posted Date
- 2015-09-07
- Lead Sponsor
- PLx Pharma
- Target Recruit Count
- 34
- Registration Number
- NCT00966641
- Locations
- 🇺🇸
Houston Institute for Clinical Research, Houston, Texas, United States
Double-blind Placebo-controlled 2-part Study Assessing the Safety, Tolerability and PK of AZD1386 in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2009-07-24
- Last Posted Date
- 2010-12-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 11
- Registration Number
- NCT00945178
- Locations
- 🇬🇧
Research Site, Harrow, United Kingdom
Study of Flavocoxid (Limbrel) Versus Naproxen in Subjects With Moderate-Severe Osteoarthritis of the Knee
- Conditions
- Interventions
- First Posted Date
- 2009-06-26
- Last Posted Date
- 2017-12-13
- Lead Sponsor
- Primus Pharmaceuticals
- Target Recruit Count
- 350
- Registration Number
- NCT00928837
- Locations
- 🇺🇸
Alan Kivitz MD, Duncansville, Pennsylvania, United States
Study Evaluating Ibuprofen 600 mg Extended Release (ER) For Dental Pain
- First Posted Date
- 2009-06-04
- Last Posted Date
- 2018-03-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 196
- Registration Number
- NCT00913627
- Locations
- 🇺🇸
Jean Brown Research Center, Salt Lake City, Utah, United States
Effect of Repeated Dosing of Naproxcinod on Renal Hemodynamic and on Sodium Balance in Healthy Volunteers Before and After a Single Dose of Furosemide
- Conditions
- Interventions
- First Posted Date
- 2009-05-28
- Last Posted Date
- 2011-06-17
- Lead Sponsor
- NicOx
- Target Recruit Count
- 31
- Registration Number
- NCT00909519
Phase I Study to Evaluate Bioavailability of Naproxen as PN400 Compared to Naproxen as Naprosyn E
- First Posted Date
- 2009-05-22
- Last Posted Date
- 2010-12-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 48
- Registration Number
- NCT00907400
- Locations
- 🇸🇪
Research Site, Uppsala, Sweden
A Study of Tanezumab in Adults With Chronic Low Back Pain
- First Posted Date
- 2009-04-06
- Last Posted Date
- 2021-07-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1359
- Registration Number
- NCT00876187
- Locations
- 🇺🇸
Comprehensive Clinical Research, Berlin, New Jersey, United States
🇺🇸Advances In Health, Inc., Houston, Texas, United States
🇺🇸Clinical Research Consortium, Las Vegas, Nevada, United States
Tanezumab in Osteoarthritis of the Hip or Knee (2)
- Conditions
- Interventions
- First Posted Date
- 2009-03-17
- Last Posted Date
- 2021-05-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 849
- Registration Number
- NCT00863304
- Locations
- 🇺🇸
HeartCare Research, Sarasota, Florida, United States
🇺🇸Spring Clinical Research, Sugar Land, Texas, United States
🇺🇸Sugar Land Med-Ped, P.A., Sugar Land, Texas, United States
Infliximab for Treatment of Axial Spondyloarthritis (P05336 AM1)
- Conditions
- Interventions
- First Posted Date
- 2009-02-16
- Last Posted Date
- 2017-04-12
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 158
- Registration Number
- NCT00844805
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.